These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 39027473)

  • 1. Metabolomic profile of secondary hyperparathyroidism in patients with chronic kidney disease stages 3-5 not receiving dialysis.
    Gan L; Wang L; Li W; Zhang Y; Xu B
    Front Endocrinol (Lausanne); 2024; 15():1406690. PubMed ID: 39027473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for Chronic Kidney Disease-Mineral and Bone Disorder Associated With Metabolic Pathway Changes.
    Wu Q; Lai X; Zhu Z; Hong Z; Dong X; Wang T; Wang H; Lou Z; Lin Q; Guo Z; Chai Y
    Medicine (Baltimore); 2015 Aug; 94(32):e1273. PubMed ID: 26266360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of serum biomarkers for chronic kidney disease using serum metabolomics.
    Gu X; Dong Y; Wang X; Ren Z; Li G; Hao Y; Wu J; Guo S; Fan Y; Ren H; Liu C; Ding S; Li W; Wu G; Liu Z
    Ren Fail; 2024 Dec; 46(2):2409346. PubMed ID: 39378112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
    Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
    Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function.
    Duranton F; Lundin U; Gayrard N; Mischak H; Aparicio M; Mourad G; Daurès JP; Weinberger KM; Argilés A
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):37-45. PubMed ID: 24235289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma metabolite biomarkers related to secondary hyperparathyroidism and parathyroid hormone.
    Shen Q; Xiang W; Ye S; Lei X; Wang L; Jia S; Shao X; Weng C; Shen X; Wang Y; Feng S; Qu L; Wang C; Chen J; Zhang P; Jiang H
    J Cell Biochem; 2019 Sep; 120(9):15766-15775. PubMed ID: 31069832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels.
    Zhao Y; Zhang LL; Ding FX; Cao P; Qi YY; Wang J
    Ren Fail; 2017 Nov; 39(1):159-165. PubMed ID: 27876426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
    Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
    Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population.
    Barbuto S; Perrone V; Veronesi C; Dovizio M; Zappulo F; Vetrano D; Giannini S; Fusaro M; Ancona DD; Barbieri A; Ferrante F; Lena F; Palcic S; Re D; Rizzi FV; Cogliati P; Soro M; Esposti LD; Cianciolo G
    Nutrients; 2023 Jan; 15(2):. PubMed ID: 36678208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The link between phenotype and fatty acid metabolism in advanced chronic kidney disease.
    Chen DQ; Chen H; Chen L; Vaziri ND; Wang M; Li XR; Zhao YY
    Nephrol Dial Transplant; 2017 Jul; 32(7):1154-1166. PubMed ID: 28339984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.
    Bozic M; Diaz-Tocados JM; Bermudez-Lopez M; Forné C; Martinez C; Fernandez E; Valdivielso JM
    Nephrol Dial Transplant; 2022 Mar; 37(4):663-672. PubMed ID: 34021359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.
    Ge Y; Yang G; Wang N; Zha X; Yu X; Mao H; Sun B; Zeng M; Zhang B; Xing C
    Int Urol Nephrol; 2019 Aug; 51(8):1443-1449. PubMed ID: 31264087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma metabolites associated with chronic kidney disease and renal function in adults from the Baltimore Longitudinal Study of Aging.
    Yamaguchi Y; Zampino M; Moaddel R; Chen TK; Tian Q; Ferrucci L; Semba RD
    Metabolomics; 2021 Jan; 17(1):9. PubMed ID: 33428023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Salam SN; Khwaja A; Wilkie ME
    Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium-mediated parathyroid hormone suppression test in uraemic secondary hyperparathyroidism.
    Xiang T; Wang Y; Lan T; Zhou L
    Nephrology (Carlton); 2021 Feb; 26(2):164-169. PubMed ID: 33058364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD.
    Zhang LN; Yang G; Cheng C; Shen C; Cui YY; Zhang J; Zhang JJ; Shen ZX; Zeng M; Ge YF; Sun B; Yu XB; Ouyang C; Zhang B; Mao HJ; Liu J; Xing CY; Zha XM; Wang NN
    Osteoporos Int; 2015 Jan; 26(1):395-405. PubMed ID: 25224292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.